Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Staks is a one-stop-shop for supplements. Their pouches contain a whole days combination of supplements in single serving sachets. Staks is ideal for people that are unsure on what supplements to take or simply don't have time to organise a supplement plan.
days to go:
Expired
investment:
£10,460
WELD is a fitness company on a mission to make on-demand health, fitness and wellbeing available to all ages & abilities. The company allows users and instructors to set the time and place for the training session, rent out their home or commercial spaces for activities, or interact 1-2-1 online. This approach, the company believes, helps personal trainers, hit by the Covid-19 lockdown, find clients. WELD also allows trainers to set their prices and keep 90% of their fees, and lets customers enjoy a 2% commission on referrals for every future session taken in perpetuity. WELD aims to tap into the $94 billion global fitness and wellness market that grew 8.7% from 2018/19. The company's primary target audience is Generation Z that, the company believes, embraced wellness. WELD will use the investment to improve its platform, boost marketing and plug the fitness & wellness gap.
days to go:
Expired
investment:
£199,227
Creating Scottish cocktails that are high quality and ready-to-drink. The Venom Project's drinks consist of 5 flavours available in cans that contain 8% alcohol and are currently sold in off-licenses in Scotland, as well as over 300 retailers. In the first 7 months of trading, the company has been listed by over 250 stockists and sold more than 150k units. This has resulted in sales of £500k with the team growing from 3 to 10 members to handle demand.
More than 250 stores have requested re-orders on a monthly basis and The Venom Project has predicted that 250k units per month will be reached in the near future. Funds will allow the company to escalate their manufacturing process to meet consumer demand, as well as acquire more stockists to attract new customers to the brand. A new manufacturing process will also allow the business to print their cans, which will aid in reducing production costs.
days to go:
Expired
investment:
£62,170
H2O-ganics is using brand new technology to transform UK crop-growing. They are able to use this technology to grow vegetables indoors, without the need for pesticides and protected from disease and environmental factors.
days to go:
Expired
investment:
£76,418
Lenderwize are a SEIS approved, UK based Crowdlending platform for Telcos. They seek to bridge the cash flow gap for telecom operators which sell to big operators and must pay their vendors upfront whilst waiting for their own clients to pay them. Lenderwize currently has a working platform with over £5,000,000 in requests from borrowers and over £9,000,000 from institutional investors.
days to go:
Expired
investment:
£78,076
KindLink are a social network for donors and charities so donors are able to make a donation to their favourite charity and help them help other people. Donors are able to see the impact of the donations they are making by following the progress of the charity and updates for the project donated to. KindLink establishes a direct connection between donor and beneficiary to create a close and community-like feel.
days to go:
Expired
investment:
£25,045
